BTK

BTK inhibitor Velexbru approved new indications: treatment of two kinds of malignant lymphoma, the total remission rate is 90%

BTK inhibitor Velexbru approved new indications: treatment of two kinds of malignant lymphoma, the total remission rate is 90%

Ono Pharmaceutical recently announced that its BTK inhibitor Velexbru (tirabrutinib hydrochloride, 80mg tablet) has been approved in Japan for the treatment of Fahrenheit macroglobulinemia (WM) and lymphocytic lymphoma (LPL). Velexbru is a highly […]

Science sub-journal: Anticancer drug acalabrutinib is expected to treat cytokine storm in patients with severe COVID-19

Science sub-journal: Anticancer drug acalabrutinib is expected to treat cytokine storm in patients with severe COVID-19

Early data from a clinical study suggest that blocking Bruton tyrosine kinase (BTK) provides clinical benefits for a small group of patients with severe COVID-19. The researchers responsible for the study observed […]

The first listed BTK inhibitor – Imbruvica

The first listed BTK inhibitor – Imbruvica

The sales of 2018 global small molecule drug apixaban replaced lenalidomide with a slight advantage, ranking first, and immediately after the two, it is the Imbruvica, the first listed BTK […]